Laboratory of Cell Biology and Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10 000 Zagreb, Croatia.
Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10 000 Zagreb, Croatia.
Oncol Rep. 2022 Jun;47(6). doi: 10.3892/or.2022.8325. Epub 2022 May 4.
Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B‑cell non‑Hodgkin lymphoma. Considering its beneficial properties in the therapy of relapsed or refractory hematological malignancies, synergistic effects with other antineoplastic agents and increasing recent reports on its immunomodulatory effects, bendamustine has once again gained its justified attention. The uniqueness of bendamustine‑mediated effects should be observed keeping in mind its distinctive structure with structural similarities to both alkylating agents and purine analogs. In the present review, the current knowledge on the use of bendamustine in oncology, its pharmacokinetics, mechanism of action and toxicity was summarized. In addition, its immune‑modulating effects that have not been fully elucidated so far are emphasized, hoping to encourage further investigations of this unique drug.
苯达莫司汀是一种烷化剂，属于氮芥类似物组，于大约六十年前合成。它于 1971 年在前东德注册，并于 2008 年被美国食品和药物管理局批准用于治疗慢性淋巴细胞白血病和惰性 B 细胞非霍奇金淋巴瘤。鉴于其在复发或难治性血液恶性肿瘤治疗中的有益特性、与其他抗肿瘤药物的协同作用以及最近越来越多的关于其免疫调节作用的报道，苯达莫司汀再次引起了人们的关注。考虑到其与烷化剂和嘌呤类似物都具有结构相似性的独特结构，应注意观察苯达莫司汀介导的作用的独特性。在本综述中，总结了苯达莫司汀在肿瘤学中的应用、药代动力学、作用机制和毒性的最新知识。此外，还强调了其迄今尚未完全阐明的免疫调节作用，希望鼓励对这种独特药物进行进一步研究。
